Literature DB >> 7583554

PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme.

A D Tselepis1, C Dentan, S A Karabina, M J Chapman, E Ninio.   

Abstract

In human plasma, platelet activating factor (PAF)-degrading acetylhydrolase (acetylhydrolase) is principally transported in association with LDLs and HDLs; this enzyme hydrolyzes PAF and short-chain forms of oxidized phosphatidylcholine, transforming them into lyso-PAF and lysophosphatidylcholine, respectively. We have examined the distribution, catalytic characteristics, and transfer of acetylhydrolase activity among plasma lipoprotein subspecies separated by isopycnic density gradient ultracentrifugation; the possibility that the plasma enzyme may be partially derived from adherent monocytes has also been evaluated. In normolipidemic subjects with Lp(a) levels < 0.1 mg/mL, acetylhydrolase was associated preferentially with small, dense LDL particles (LDL-5; d = 1.050 to 1.063 g/mL) and with the very-high-density lipoprotein-1 subfraction (VHDL-1; d = 1.156 to 1.179 g/mL), representing 23.9 +/- 1.7% and 20.6 +/- 3.2%, respectively, of total plasma activity. The apparent Km values for PAF of the enzyme associated with such lipoproteins were 89.7 +/- 23.4 and 34.8 +/- 4.5 mumol/L for LDL-5 and VHDL-1, respectively: indeed, the Km value for LDL-5 was some 10-fold higher than that of the light LDL-1, LDL-2, and LDL-3 subspecies, whereas the Km of VHDL-1 was some twofold greater than those of the HDL-2 and HDL-3 subspecies. Furthermore, when expressed on the basis of unit plasma volume, the Vmax of the acetylhydrolase associated with LDL-5 was some 150-fold greater than that in LDL-1 (d = 1.019 to 1.023 g/mL). No significant differences in the pH dependence of enzyme activity or in sensitivity to protease inactivation, sulfydryl reagents, the serine protease inhibitor Pefabloc, or the PAF antagonist CV 3988 could be detected between apo B-containing and apo A-I-containing lipoprotein particle subspecies. Incubation of LDL-1 (Km = 8.4 +/- 2.6 mumol/L) and LDL-2 (d = 1.023 to 1.029 g/mL; Km = 8.4 +/- 3.3 mumol/L) subspecies with LDL-5, in which acetylhydrolase had been inactivated by pretreatment with Pefabloc, demonstrated preferential transfer of acetylhydrolase to LDL-5. Acetylhydrolase transferred to LDL-5 from the light LDL subspecies exhibited a Km of 9.4 +/- 2.2 mumol/L, a value characteristic of the particle donors. Finally, acetylhydrolase (Km = 23.4 +/- 7.6 mumol/L) released by adherent human monocytes in culture was found to bind preferentially to small, dense LDL subspecies upon incubation of Pefabloc-inactivated plasma with monocyte supernatant.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7583554     DOI: 10.1161/01.atv.15.10.1764

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  37 in total

1.  Platelet-activating factor acetylhydrolase and transacetylase activities in human plasma low-density lipoprotein.

Authors:  D C Tsoukatos; T A Liapikos; A D Tselepis; M J Chapman; E Ninio
Journal:  Biochem J       Date:  2001-07-15       Impact factor: 3.857

2.  Involvement of phospholipids in apolipoprotein B modification during low density lipoprotein oxidation.

Authors:  A I Karakatsani; T A Liapikos; A N Troganis; D C Tsoukatos
Journal:  Lipids       Date:  1998-12       Impact factor: 1.880

Review 3.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

4.  Plasma levels of lipoprotein-associated phospholipase A(2) are increased in patients with β-thalassemia.

Authors:  Alexandros D Tselepis; George Hahalis; Constantinos C Tellis; Eleni C Papavasiliou; Panagiota T Mylona; Alexandra Kourakli; Dimitrios C Alexopoulos
Journal:  J Lipid Res       Date:  2010-07-12       Impact factor: 5.922

5.  Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A₂ in subjects with prediabetes.

Authors:  Theodosios D Filippatos; Evangelos C Rizos; Vasilios Tsimihodimos; Irene F Gazi; Alexandros D Tselepis; Moses S Elisaf
Journal:  Lipids       Date:  2013-04-02       Impact factor: 1.880

6.  Association of Lp-PLA(2) activity with allele-specific Lp(a) levels in a bi-ethnic population.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Thomas A Pearson; Lars Berglund
Journal:  Atherosclerosis       Date:  2010-04-20       Impact factor: 5.162

7.  The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of apoB/Lp-PLA₂.

Authors:  Constantinos C Tellis; Eliza Moutzouri; Moses Elisaf; Robert L Wolfert; Alexandros D Tselepis
Journal:  J Lipid Res       Date:  2013-10-03       Impact factor: 5.922

8.  Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome.

Authors:  K G Lagos; T D Filippatos; V Tsimihodimos; I F Gazi; C Rizos; A D Tselepis; D P Mikhailidis; Moses S Elisaf
Journal:  Lipids       Date:  2008-10-28       Impact factor: 1.880

Review 9.  Role of platelets in neuroinflammation: a wide-angle perspective.

Authors:  Lawrence L Horstman; Wenche Jy; Yeon S Ahn; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; J Steven Alexander; Alireza Minagar
Journal:  J Neuroinflammation       Date:  2010-02-03       Impact factor: 8.322

10.  Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study.

Authors:  Sunil Suchindran; David Rivedal; John R Guyton; Tom Milledge; Xiaoyi Gao; Ashlee Benjamin; Jennifer Rowell; Geoffrey S Ginsburg; Jeanette J McCarthy
Journal:  PLoS Genet       Date:  2010-04-29       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.